-       Report 
- November 2024
-  120 Pages 
- Global 
   From       €5322EUR$5,950USD£4,681GBP 
            -       Report 
- October 2025
-  184 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
          -       Report 
- October 2025
-  310 Pages 
- Global 
   From       €5233EUR$5,850USD£4,603GBP 
          -       Report 
- April 2025
-  200 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- May 2025
-  185 Pages 
- Global 
   From       €4025EUR$4,500USD£3,541GBP 
           -       Report 
- August 2025
-  155 Pages 
- Global 
   From       €2370EUR$2,650USD£2,085GBP 
          -       Report 
- April 2025
-  255 Pages 
- Global 
   From       €4428EUR$4,950USD£3,895GBP 
          -       Report 
- March 2025
-  451 Pages 
- Global 
   From       €4428EUR$4,950USD£3,895GBP 
            -       Report 
- September 2025
-  150 Pages 
- Global 
   From       €5322EUR$5,950USD£4,681GBP 
          -       Report 
- December 2024
-  150 Pages 
- Global 
   From       €5322EUR$5,950USD£4,681GBP 
            -       Report 
- October 2025
-  184 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- October 2025
-  185 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- October 2025
-  190 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- August 2025
-  183 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- August 2025
-  185 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
          -       Report 
- October 2025
-  381 Pages 
- Global 
   From       €5233EUR$5,850USD£4,603GBP 
          -       Report 
- October 2025
-  129 Pages 
- Global 
   From       €5233EUR$5,850USD£4,603GBP 
          -       Report 
- February 2025
-  200 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- February 2025
-  200 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- February 2025
-  200 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
       
      The Patient Derived Xenograft (PDX) market is a rapidly growing segment of the drug discovery industry. PDX models are derived from human tumors that are implanted into immunodeficient mice, allowing researchers to study the effects of drugs on human cancer in a living system. PDX models are used to identify new drug targets, evaluate drug efficacy, and assess drug safety. They are also used to study the biology of cancer and to develop personalized treatments. PDX models are increasingly being used    in clinical trials to evaluate the efficacy of new drugs.
PDX models offer several advantages over traditional cell-based models, including the ability to study the effects of drugs on a living system, the ability to study the effects of drugs on multiple tumor types, and the ability to study the effects of drugs on the tumor microenvironment.
Companies in the PDX market include Charles River Laboratories, Crown Bioscience, Horizon Discovery, and Taconic Biosciences. Show Less   Read more